Clinical Trial

Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS

Study acronym: PCOS FAI CHC
Completed
View on ClinicalTrials.gov →
Summary
Combined hormonal contraceptive (CHC) improves androgen parameter in women with PCOS. High-dose CHC increases insulin resistance, whereas low dose CHC has minimal effects on carbohydrate metabolism. This quasi experimental study was conducted to compare the effects of Drospirenone-Ethinyl Estradiol (20µg) to that with Drospirenone-Ethinyl Estradiol (30µg) on free androgen index (FAI) in polycystic ovary syndrome. Medication was given for 3 months. FAI, HOMA-IR was measured in baseline and after treatment and results were compared.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-23.
Trial Details
NCT Number NCT07318337
Lead Sponsor Mst.Sumyara Khatun
Collaborators: Bangladesh Medical University
Conditions PCOS (Polycystic Ovary Syndrome)
Enrollment 60 participants
Start Date 2024-07-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-09